Alyeska Investment Group
CHRS icon

Alyeska Investment Group’s Coherus Oncology CHRS Stock Holding History

Alyeska Investment Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.8M Buy
+2,250,000
New +$4M 0.01% 505
2018
Q4 		– Sell
-100,000
Closed -$1.65M – 377
2018
Q3 		$1.65M Sell
100,000
-298,717
-75% -$5.3M 0.02% 316
2018
Q2 		$5.58M Sell
398,717
-57,860
-13% -$828K 0.05% 266
2018
Q1 		$5.04M Sell
456,577
-28,004
-6% -$306K 0.04% 287
2017
Q4 		$4.26M Sell
484,581
-75,000
-13% -$803K 0.03% 273
2017
Q3 		$7.47M Sell
559,581
-26,446
-5% -$350K 0.06% 267
2017
Q2 		$8.41M Buy
586,027
+136,027
+30% +$2.62M 0.07% 252
2017
Q1 		$9.52M Buy
+450,000
New +$11.1M 0.08% 261
2015
Q1 		– Sell
-34,183
Closed -$558K – 502
2014
Q4 		$558K Buy
+34,183
New +$482K 0.01% 434

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Alyeska Investment Group's CHRS Position: Q1 2026 in Review

Alyeska Investment Group opened a new position in Coherus Oncology (CHRS) in Q1 2026: 2,250,000 shares worth $3.8M. The stake represents 0.01% of the portfolio and ranks #505 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in CHRS as recently as Q3 2018.

Alyeska Investment Group first reported a position in CHRS in Q4 2014 and has held it in 9 quarters since. The position peaked at $9.52M in Q1 2017. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Alyeska Investment Group held 2,250,000 shares of Coherus Oncology worth $3.8M as of Q1 2026.
  • Coherus Oncology was a new Alyeska Investment Group position in Q1 2026.
  • Coherus Oncology made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #505 holding.
  • Alyeska Investment Group first reported a position in Coherus Oncology in Q4 2014 and has held it in 9 quarters since.
  • Alyeska Investment Group's Coherus Oncology position peaked at $9.52M in Q1 2017.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.